Halozyme Therapeutics Names New Chief Financial Officer

Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology, and drug delivery markets, today announced the appointment of Kurt Gustafson as Vice President, Finance. Mr. Gustafson will assume the role of Chief Financial Officer on May 15. David Ramsay, Halozyme’s current CFO, will transition to the new position of Vice President, Corporate Development.

"We are delighted to welcome an individual with Kurt’s industry experience, stature and expertise as an integral new member of our executive leadership team at Halozyme,” said Jonathan Lim, M.D., President and CEO. "Kurt’s knowledge and experience will be of tremendous value as we enter the next phase of our growth. This transition of senior management exemplifies one of our core values, which is to recruit, develop and retain exceptional talent and to provide new opportunities and foster professional growth within our organization.”

Mr. Gustafson brings to Halozyme’s senior management team a unique combination of operational and managerial experience in financial planning and analysis, accounting, treasury, and international responsibility gained during his 18 years with Amgen. In his most recent position, as Vice President, Manufacturing Finance, Mr.Gustafson was responsible for financial planning and cost accounting for each of Amgen’s worldwide manufacturing sites and the Cost Accounting Group. Some of his previous positions at Amgen include: Vice President, Finance and CFO of Amgen Europe with responsibility for financial planning and accounting for European operations from 2004-2006, head of corporate financial planning and analysis from 2000-2004, and treasurer from 1998-2000. Before joining Amgen, he was with the accounting firm Laventhol & Horwath in Chicago. He received his BS in accounting from North Park University in Chicago and an MBA from UCLA.

David Ramsay joined Halozyme as Chief Financial Officer in 2003. His numerous achievements and accomplishments at Halozyme include spearheading the process of taking Halozyme public in 2004, closing multiple rounds of financing to help the company raise over $180 million, including equity investments made by Roche and Baxter, supporting the Roche and Baxter collaborations, negotiating and signing the Baxter HYLENEX collaboration, establishing and developing the company’s accounting, financial, and IT infrastructure, and implementing Sarbanes-Oxley compliance rules.

"I am thrilled that David will be leading corporate development efforts at Halozyme, and greatly appreciate his many years of outstanding service as CFO,” said Jonathan Lim. "Halozyme would not be where it is today without David’s commitment to excellence, unwavering dedication, and significant accomplishments. I will continue to rely on his counsel and guidance and eagerly look forward to working with him in his new role.”

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme’s Enhanze™ Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze Technology to Roche’s biological therapeutics for up to 13 targets and with Baxter BioScience to apply Enhanze Technology to Baxter’s biological therapeutic compound, GAMMAGARD LIQUID. Halozyme’s research pipeline candidates target significant areas of unmet medical need. For more information visit www.halozyme.com.

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the CFO transition plan) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.